After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The vaccine will only be available to those at high risk from COVID—excluding those who may need it to protect a relative or ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

Novavax Inc. jumped as US regulators fully approved its Covid vaccine, easing investors’ concerns after the clearance was ...

Key Takeaways Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine.The shot, ...

Novavax had expected full approval for broader use by April 1, after the FDA reviewed data from a 30,000-person clinical ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

Novavax today announced that the US Food and Drug Administration (FDA) has approved full licensure for its COVID-19 vaccine, ...

The approval restricts use to older people and adolescents or adults with risk factors — a first for a COVID-19 vaccine. Perspective from Aaron E. Glatt, MD, FACP, FIDSA, FSHEA The FDA has approved ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...